The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment.
Launched by SHANGHAI CHANGZHENG HOSPITAL ยท
Trial Information
Current as of November 12, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment for people with moderate to severe thyroid-associated ophthalmopathy (TAO), a condition linked to thyroid disease that affects the eyes. TAO can cause eye swelling, pain, and in serious cases, vision problems or even blindness. The trial is testing a medicine called IBI311, which is designed to block certain signals that cause harmful changes in the eye tissues. Researchers want to see how well IBI311 works compared to the usual treatment with hormone therapy, and to make sure it is safe for patients.
People eligible for this study are adults with active moderate to severe TAO who are starting treatment for the condition. If you join the trial, you will receive either the new IBI311 treatment or the standard hormone therapy, and the doctors will carefully monitor your response and any side effects. This study aims to find better treatment options to help protect eyesight and improve quality of life for people living with TAO.
Gender
ALL
Eligibility criteria
About Shanghai Changzheng Hospital
Shanghai Changzheng Hospital, affiliated with the Second Military Medical University, is a leading medical institution in China known for its comprehensive clinical services and advanced research capabilities. With a commitment to improving patient outcomes and advancing medical knowledge, the hospital actively engages in clinical trials across various therapeutic areas. Its multidisciplinary team of healthcare professionals collaborates with researchers and industry partners to facilitate innovative studies, ensuring adherence to the highest ethical and regulatory standards. By leveraging its state-of-the-art facilities and expertise, Shanghai Changzheng Hospital aims to contribute significantly to the development of new treatments and therapies that enhance patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported